<u>Page 1 of 16</u> ATTY. DOCKET NO. 09 \$ 529,69 0652.2050000 FORM PTO-1449 APPLICANT Wagner et al. INFORMATION DISCLOSURE STATEMENT GROUP 102(e) DATE June 22, 2000 U.S. PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT DATE NAME CLASS SUB-FILING DATE NUMBER CLASS AA AB AC AD ΑE AF AG AH ΑI ДJ AK FOREIGN PATENT DOCUMENTS EXAMINER SUB-TRANSLATION DOCUMENT DATE COUNTRY CLASS INITIAL NUMBER CLASS Yes AL1 WO 93/07906 04/29/1993 WIPO No Abstract Yes AM1 WO 93/10219 05/27/1993 WÌPO No Abstract Yes WO 94/21808 09/29/1994 WIPO AN1 No Yes AO1 WO 95/09655 04/13/1995 WIPO No DE 44 11 425 Abstract Yes 10/19/1995 AP1 Germany A1 No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) $Barth, \cdot A.$, et al., "Polyvalent Melanoma Cell Vaccine Induces Delayed-Type Hypersensitivity and In Vitro Cellular Immune Response, " Cancer Res. 54:3342-3345 AR 1 (1994).Belli, F., et al., "Active Immunization of Metastatic Melanoma Patients with AS 1 Interleukin-2-Transduced Allogeneic Melanoma Cells: Evaluation of Efficacy and Tolerability, " Cancer Immunol. Immunother. 44:197-203 (June 1997). Berd, D., et al., "Treatment of Metastatic Melanoma with an Autologous Tumor-Cell ΑТ Vaccine: Clinical and Immunologic Results in 64 Patients," J. Clin. Oncol. 1 8:1858-1867 (1990). DATE CONSIDERED EXAMINER 8119101

EXAMINER: Initial preference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in conformance and not considered. Include copy of this form with next communication to Applicant.

ALCENTED.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000

APPLICATION 09/529,659

APPLICANT
Wagner et al.

102(e) DATE

GROUP 1/(10)

GROUP 1642 ROBLERY SEED

					102(e) DATE June 22, 2000		GR00P <1643	16428	OFMAN CEET
				U.	S. PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE
	AA								
	АВ								
	AC						<u> </u>		
	AD								
	AE								
	AF								
	AG								
	АН					·-	_		
	AI				** W.				
	AJ								ļ
	AK								
				FORE	IGN PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
el.	AL2	WO 9	5/31107	11/23/1995	WIPO		<u> </u>		Y e
V	AM2	WO 9	7/30721	08/28/1997	WIPO				Abstract Ye
	AN2	DE 1	96 07 044 A1	08/28/1997	Germany				Abstract Ye
$\overline{\gamma}$	AO								Y 6
	AP								Y e
-	17	<u> </u>	OTHER (Including Autho	or, Title, Date, Pertin	ent Pages.	etc.)		-
8	AR	2	Immunity: F	reparation. Ch	sicles for Tumour-Assoc aracterization and Enh rolled Release 29:317-3	ancement of	gen Prepara the Immune	tion to Induc Repsonse by	ce Protective
	AS	2	Buschle, M., Cells," <i>Proc</i>	et al., "Trans. Natl. Acad. S	sloading of Tumor Antig Sci. 94:3256-3261 (Apri	gen-Derived l 1997).	Peptides i	nto Antigen-F	Presenting
	АТ	<u>2</u>	Clary, B.M., Immunotherap April 1997).	y with Interle	bition of Established F ukin-2 Gene-Transduced	Pancreatic Tumor Cell	Cancers Fol s," Cancer (lowing Specif Gene Ther. 4:	fic Active 97-104 (March-
EXAMINER	- POX		0				DATE CONSID	DERED 81	19/0/

EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

									Page 3 of 16
					ATTY. DOCKET NO. 0652.2050000		APPLIC/ 09/529	ATION NO. 0	IPE
			то-1449		APPLICANT Wagner et al.	<u>-</u>	-	NOV O	7 2000
. <u>IN</u>	FORMATIC	ON DISC	CLOSURE STATE	<u>MENI</u>	102(e) DATE June 22, 2000		GROUP	602	- 4000 u
				U.S.	PATENT DOCUMENTS			RADE	MARKOF
EXAMINER									
INITIAL		DOCUM	MENT NUMBER	DATE	NAME	CL	ASS	SUB-CLASS	FILING DATE
	AA	 				 			
	AB AC	├							
	AD	\vdash			: -				
	AE	 	*					<u> </u>	
	AF								
	AG								
	АН								
	ΑI								
	AJ								
	AK								
				FOREI	GN PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUM	MENT NUMBER	DATE	COUNTRY	СГ	.ASS	SUB-CLASS	TRANSLATION
	AL								Yes No
	АМ								Yes No
	AN		-		•				Yes No
		<u> </u>					,		Yes No
	AO								Yes
	AP	<u> </u>							No.
	- 		OTHER (Including Author	, Title, Date, Pertinent	Pages, etc.)		
	AR	<u>3</u>	Clary, B.M. Engineered	, et al., "Active to Secrete Multip	e Immunotherapy of Pancre ble Cytokines," Surgery 1.	atic Cancer 20:174-181 (with Tun (August 1	nor Cells Ge 996).	enetically
	AS	<u>3</u>	Cleland, J.I Interferon- (October 199	γ for Microencap	.J.S., "Stable Formulatio sulation in Biodegradable	ons of Recom Microspher	binant Hu es," <i>Phai</i>	uman Growth om. Res. 13:	Hormone and 1464-1475
	AT	3	Granulocyte	-Macrophage Colo	nation with Irradiated Tu ny-Stimulating Factor Sti Natl. Acad. Sci. USA 90:3	mulates Pot	ent, Spec	i to Secrete cific, and l	e Murine Long-Lasting
EXAMINER	RD	an	ng Q			DATE	CONSIDE	RED 811	9 (0)
EXAMINER: Init	ial i	referen	nce consider	ed, whether or no	ot citation is in conformude copy of this form wit	mance with M	PEP 609. unication	Draw line n to Applica	through

		FORM I	PTO-1449		ATTY. DOCKET NO. 0652.2050000 APPLICANT		9/529,659 /	0 7 2000
<u>1</u>	NFORMATI	ON DIS	CLOSURE STATE	<u>EMENT</u>	Wagner <i>et al</i> . 102(e) DATE June 22, 2000	G	ROUP 1622	- 13
				U.	S. PATENT DOCUMENTS			DEMARK OF
EXAMINER INITIAL	T	DOCL	JMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							<u> </u>
	AC							
	AD	-			-	_ 		
	AE	├	<u>-</u>	-				
	AF	 			<u> </u>		-	
	AG AH	+					-	
	AI	+-				· · · · · · · · · · · · · · · · · · ·		
	AJ	T		· · ·				
	AK							
				FORE	IGN PATENT DOCUMENTS			
EXAMINER		2001	MENT NUMBER	DATE	COUNTRY	CLASS	S SUB-CLASS	TRANSLATION
INITIAL	1	DOCL	JMENT NUMBER	DATE	COUNTRY	·	SUB CEASS	Yes
	AL	 			-	**		Yes
	AM	+	·		-			Yes
	AN	-		<u> </u>			. 400	Yes
	AO			-				Yes
	AP	<u> </u>			or, Title, Date, Pertine			No.
8	AR	<u>4</u>	Eppstein. D	.A., "Altered P	harmacologic Properties 117-125 (1982).	_	ciated Human Int	erferon-Alpha.
	AS	<u>4</u>	Fearon, E.R Generation	., et al., "Int of an Antitumor	erleukin-2 Production by Response," <i>Cell 60:</i> 397 -	/ Tumor Cells Bypa 403 (1990).	asses T Helper F	unction in the
	AT	4	Results in	CD8+ T Cell-Med	FN-α1 Gene Expression Ir liated Tumor Rejection ar FN-γ-Producing TS/A Cel	nd Development of	Antitumor Immun	ity.
EXAMINER	Å	De	usul	-		DATE CO	DNSIDERED 8.1	19/01
EXAMINER: Ini	tial if	ne ere	ence consider	ed, whether or onsidered. Inc	not citation is in confo	ormance with MPEP	609. Draw line cation to Applic	through

FCFIVE OS OF Page 5 of 16 CATION NO ATTY. DOCKET NO. 09/529,659 GROUP. <u> 1643</u>) SUB-CLASS FILING DATE CLASS SUB-CLASS TRANSLATION **CLASS** Yes No Yes No Yes No Yes No Yes

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT

0652.2050000 APPLICANT Wagner et al. 102(e) DATE

June 22, 2000 U.S. PATENT DOCUMENTS **EXAMINER** DOCUMENT NUMBER DATE INITIAL AA AB AC ΑD ΑE ΑF AG ΑН ΑI ΑJ ΑK FOREIGN PATENT DOCUMENTS **EXAMINER** COUNTRY DOCUMENT NUMBER DATE INITIAL ΑL AM AN ΑO AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Fujiwara, T., et al., "Application of An Interleukin 2 Slow Delivery System to the Immunotherapy <u>5</u> AR of Established Murine Colon 26 Adenocarcinoma Liver Metastases," Cancer Res. 50:7003-7007 (1990). Gansbacher, B., et al., "Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity 5 and Induces Protective Immunity," J. Exp. Med. 172:1217-1224 (1990). Golumbek, P.T., et al., "Conrolled Release, Biodegradable Cytokine Depots: A New Approach in Cancer Vaccine Design," Cancer Res. 53:5841-5844 (1993). <u>5</u> ΑT

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

									Page 6 of 16
					ATTY. DOCKET NO 0652.2050000	0.	APPLIO 09/529	CATION NO.	O'LER
.,			PTO-1449	MENT	APPLICANT Wagner et al.			ATE NOV	0 7 200n G
11	YFUKMA] I	ON DIS	SCLOSURE STATE	<u>IPENI</u>	102(e) DATE June 22, 2000		GROUP	1648	ist ^{al}
					U.S. PATENT DOCUMENTS			D	MARK
EXAMINER		T	-						
INITIAL	ļ	DOCL	JMENT NUMBER	DATE	NAME	_	CLASS	SUB-CLASS	FILING DATE
	AA AB	+					,,		
	AC	1							
	AD								
	AE						,		
	AF	<u> </u>						<u> </u>	
	AG	 						 	
	AH	 		<u> </u>		.			
	AJ	+	<u></u> .					 	
	AK	1	-"			v		Ī	
	<u> </u>	•		FC	REIGN PATENT DOCUMENT	rs			
EXAMINER							51.456	CUID CLASS	TRANSLATION
INITIAL	1	DOCL	JMENT NUMBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION Yes
	AL								No
									Yes No
	AM								Yes
	AN	<u> </u>							No Yes
	AO								No
	AP								Yes No
	•		OTHER (Including Aut	hor, Title, Date, Per	rtinent Pages, e	tc.)		
B	AR	<u>6</u>	Herrmann, J Activity,"	., et al., "I Eur. J. Pharm	nterferon-γ Liposomes . <i>Biopharm. 41</i> : 361-36 8	: Drug Binding F 3 (1995).	Properties	and Antivira	al in vitro
	AS	<u>6</u>	Jaffee, E.M Vaccines,"	., et al., "E J. Immunothe	nhanced Immune Primin - 19:176-183 (May 199	g with Spatial D 96).	Distributio	n of Paracri	ne Cytokine
	AT	<u>6</u>	Johnson, O. Growth Horm	L., et al., " one," <i>Nature l</i>	A Month-long Effect f Med. 2:795-799 (July	rom a Single Inj 1996).	ection of	Microencapsu	ulated Human
EXAMINER	Serv	lin	20			D	ATE CONSID	ERED S	9/01
EXAMINER: Ini	tial of	petere	ence consider	ed, whether o	r not citation is in nclude copy of this f	conformance with	MPEP 609.	Draw line	through
citation if no	t in € on	rormar	ice and not co	unstuered. I	nctude copy of this t	OTHER TOTAL CO	ANTHUM I I COLIC	" to Applica	4116.6

									Orland 16
					ATTY. DOCKET NO.			ATION NO.	
		FORM P	TO-1449		0652.2050000 APPLICANT		09/529		7 2000
TA	IEODMAT 1	אר אר	CLOSURE STATE	MENT	Wagner et al.			图	, 2000
	II OKHATI	<u> </u>	DEGGORE GIATE		102(e) DATE June 22, 2000		GROUP 1643	1642	DEMARK DETE
				U.S.	. PATENT DOCUMENTS				
EXAMINER								CUD CLASS	FILING DATE
INITIAL	AA	DOCU	MENT NUMBER	DATE	NAME	CLA	155	SUB-CLASS	FILING DATE
	AB				",		· · · ·		
	AC								
	AD			*****					
	AE								
	AF								
	AG								
	АН	<u> </u>							
	AI	<u> </u>	·						
· · · · · · · · · · · · · · · · · · ·	AJ	-						i	
	AK								
	T	1		FORE I	GN PATENT DOCUMENTS			I	
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CL.	ASS	SUB-CLASS	TRANSLATION
									Yes
	AL	 							No Voc
	AM								Yes No
		ĺ			•				Yes
	AN	-							No
	AO								Yes No
		<u> </u>							Yes
	AP		 :						No
			OTHER'(Including Author	, Title, Date, Pertinent Pag	es, etc.)		
	AR	Z	Kedar, E., 6 Interleukin 16:47-59 (19	-2 Encapsulated	y of Cytokines by Liposomes. in Long-circulating Sterical	I. Prepa ly Stabil	ration a	and Characte posomes," J.	erization of Immunother.
	AS	Z .	Lamont, A.G. 17:214-217 (., and Adorini, ((May 1996).	L., "IL-12: A Key Cytokine i	n Immune	Regulat	ion," Immuno	ol. Today
	AT	7	Lee, H.J., e	et al., "In Vivo . Pharmacol. Exp.	Characterization of Sustaine Ther. 281:1431-1439 (June 1	ed-releas 997).	e Formul	ations of H	uman Growth
EXAMINER		RIC	more			DATE	CONSIDE	RED 8	9/01
EXAMINER: Init	tial if	refere	nce consider	ed, whether or no	ot citation is in conformance	e with MP	EP 609.	Draw Uine	through

£ 16 APPLICATION NO. ATTY. DOCKET NO. 09/529,65 0652.2050000 NOV 0 7 2000 FORM PTO-1449 APPLICANT Wagner et al. INFORMATION DISCLOSURE STATEMENT GROUP 16 40 00 102(e) DATE June 22, 2000

					June 22, 2000		43 1640×	EDF MAN DY
				ບ.ຣ	. PATENT DOCUMENTS			
EXAMINER INITIAL		DOC NUM	UMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA							
	AB			<u> </u>				
	AC	<u> </u>						
	AD	<u> </u>						
	AE							
-	AF							
	AG							
	AH							
	AI							
	AJ							
	AK			1				
		· · · · · · · ·	·	FOREI	GN PATENT DOCUMENTS			
EXAMINER INITIAL			UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Ye: No
	AM							Ye: No
	AN							Ye: No
	ÀO							Yes No
	AP							Ye:
			OTHER (Inc	luding Author	, Title, Date, Pert	inent Pages, etc	··)	
	AR	<u>8</u>			Application of the I			man Renal Cell
	AS	<u>8</u>	Maulding, Release 6	H.V., "Prolo :167-176 (198	onged Delivery of Pe 87).	eptides by Micro	capsules,"	J. Controlled
	АТ	<u>8</u>	Melief, C 8:651-657	.J.M., et al. (October 199	., "Peptide-based Ca 96).	ancer Vaccines,"	Curr. Opin	. Immunol.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through extation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

						·				(ag) 5 of 16
				-		ATTY. DOCKET NO. 0652.2050000	-	APPLIC 09/529	ATION NO.	The last
			FORM I	PTO-1449		APPLICANT			ATEN.	7 2000 E
	INI	FORMAT I	ON DIS	CLOSURE STATE	<u>EMENT</u>	Wagner et al.				
						102(e) DATE June 22, 2000	<	GROUP 1643	642 6	a digital
						.S. PATENT DOCUMENTS				MARIN
EXAMINER			DOC	MENT NUMBER	DATE	NAME	CI.	ASS	SUB-CLASS	FILING DATE
INITIAL			DOCC	IMENT NUMBER	DATE	NAPIC		N33	SOB GENOG	TIETHO DATE
		AA AB	+							
		AC	+			 .	-			-
		AD	+					. <u>.</u> .		
		AE	+							
		AF	+							
		AG	+	<u> </u>						
		AH	+							
		AI								
		AJ	+							
		AK	╅							
		AK	-1		FOI	REIGN PATENT DOCUMENTS		_		
EXAMINER			T -							
INITIAL			DOCL	MENT NUMBER	DATE	COUNTRY	CL	ASS	SUB-CLASS	TRANSLATION
										Yes
		AL	 							No Yes
		АМ								No
· · · · · · ·										Yes
		AN			ļ <u>-</u>					No.
										Yes No
	·	AO	<u> </u>							Yes
		AP								NoNo
	•			OTHER (Including Auti	nor, Title, Date, Perti	nent Pages, etc.)		
To the second	! !	AR	2			ncorporation of Recombi leal Macrophage Antitoxo				
		AS	9	Morton, D.L Immunothera	., et al., "Pr py with a New	olongation of Survival Polyvalent Melanoma Vac	in Metastatic Me ccine," <i>Ann. Surg</i>	elanoma 1. 216:40	after Active 53-482 (1992	Specific).
		AT	9	Pardoll, D.1	M., "Paracrine	Cytokine Adjuvants in	Cancer Immunothe	erapy,"	Ann. Rev. Im	muno1. 13 :399-

EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

EXAMINER

DATE CONSIDERED

APPLICATION 19.

FORM PTO-1449

communication to Applicant.

INFORMATION DISCLOSURE STATEMENT

					June 22, 2000	164	3 1642	WEMARK OF
· · · · · · · · · · · · · · · · · · ·				ט	.s. PATENT DOCUMENTS			MADI
EXAMINER [NITIAL		DOCU	UMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DAT
	AA		,					
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
	AJ							
	AK							
				FOR	EIGN PATENT DOCUMENTS			
XAMINER NITIAL		DOC	UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATIO
	AL							Y
	AM							Y
	AN							Y
	AO							Y
	AP							. У
	•		OTHER (In	cluding Auth	or, Title, Date, Pert	inent Pages, etc.)	•
	AR	10	Metastat		. "Weekly 24-hour Cont and Renal Cell Carcir			
1	AS	10			., "Antimetastatic Vac -inserted Tumor Cells,			
	AT	10			al., "Experience with Cancer Patients," Ar			
XAMINER C	90)a	- sa ()			DATE CON	SIDERED	4

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next

RECEIVED

(A) 1990 N APPLICATION NO ATTY. DOCKET NO. 09/529,659 0652.2050000 ECH CENTER 160 FORM PTO-1449 0 7 2000 APPLICANT Wagner et al. INFORMATION DISCLOSURE STATEMENT 102(e) DATE **GROUP** June 22, 2000 U.S. PATENT DOCUMENTS **EXAMINER** DOCUMENT NUMBER NAME CLASS SUB-CLASS FILING DATE DATE INITIAL AΑ AB AC AD ΑE ΑF AG ΑН ΑI ΑJ ΑK FOREIGN PATENT DOCUMENTS **EXAMINER** CLASS SUB-CLASS TRANSLATION INITIAL DOCUMENT NUMBER DATE COUNTRY Yes AL No Yes No ΔM Yes No ΑN Yes No AO Yes No AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Rosenberg, S.A., "Immunotherapy and Gene Therapy of Cancer," Cancer Res. 51(Supp 18):5074s-5079s AR <u>11</u> (1991). Rosenberg, S.A., et al., "Initial Proposal of a Clinical Research Project," Hum. Gene Ther. 3:75-AS <u>11</u> 91 (1992). Rosenberg, S.A., "Immunotherapy of Patients with Advanced Cancer Using Interleukin-2 Alone with or in Combination with Lymphokine Activated Killer Cells," in Important Advances in Oncology, V. ΑT de Vita, et al., eds., J.B. Lippincott, Philadelphia, pp. 217-257 (1988). DATE CONSIDERED EXAMINER 01 reference considered, whether or not citation is in conformance with MPEP 609. Draw line through EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line thr citation if not a conformance and not considered. Include copy of this form with next communication to Applicant.

NOV 0.9 2001

Page 12 of 16

APPLICANT INFORMATION DISCLOSURE STATEMENT U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS SUB-CLASS FILING DATE INTITIAL AB AC AC AC AC AC AC AC AC AC	·					0652.2050000		99/529,6	10N NO.	OIA
U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS EXAMINER INITIAL AA AB AC AC AC AC AC AC AC AC			FORM	PTO-1449					<i>b</i>	
U.S. PATENT DOCUMENTS EXAMINER INITIAL AA AB AC AC AD AF AF AF AG AI AI AI AI AI AI AI AI AI	<u> 11</u>	FORMAT	ON DIS	CLOSURE STATE	<u>EMENT</u>	···		CPOLID 4		7 2000 8
EXAMINER AN DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING DATE AA AB A								4643- 6	1424	w w
EXAMINER INITIAL AA DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING DATE FILING DATE AB AC					u.s	. PATENT DOCUMENTS	· ·		V\$	TO SEE SEE
AA AB AB AB AC						NAME		,,,,		
AS AC	INITIAL	1	DOCL	MENI NUMBER	DATE	NAME	CL	.833	OB-CLA33	TIEING DATE
AC AD AE AF AF AG AN AN AI AI AI AI AI AI AI AI			+	÷.						
AD AE AF AG AG AI AI AI AJ AX EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY FOREIGN PATENT DOCUMENTS EVAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No No Yes No Yes No TRANSLATION Yes No Yes No AN AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR 12 Rosenstein, M., et al., "Extravasation of Intravascular Fluid Mediated by the Systemic Administration of Recombinant Interleukin 2," J. Immunol. 137:1735-1742 (1986). AS 12 Saravolac, E.G., et al., "Effect of Liposome-encapsulation on Immunomodulating and Antiviral Activities of Interferon-y," Antiviral Res. 29:199-207 (March 1996). EXAMINER: Initial Activities of Interfered whether or not citation is in conformance with MPEP 609. Draw line through		+								
AF AG AG AG AH AH AI AI AI AJ AJ AJ AN	-	+	\top	-						
AG AH AH AI		AE								
AN AI		AF								
AI AJ AK FOREIGN PATENT DOCUMENTS EXAMINER AL BOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No AM AM Yes No AM Yes No AM	-	AG								
FOREIGN PATENT DOCUMENTS EXAMINER: INITIAL DOCUMENT NUMBER DATE COUNTRY AL AL AN AN AN AN AN AN AN AN		АН								
FOREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION AL Ves No		AI								
EXAMINER EXAMINER EXAMINER DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No AM AN AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR 12 Rosenstein, M., et al., "Extravasation of Intravascular Fluid Mediated by the Systemic Administration of Recombinant Interleukin 2," J. Immunol. 137:1735-1742 (1986). AS 12 Saravolac, E.G., et al., "Effect of Liposome-encapsulation on Immunomodulating and Antiviral Activities of Interferon-y," Antiviral Res. 29:199-207 (March 1996). EXAMINER EXAMINER DATE CONSIDERED		1								
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Press No Part Number No Part Number No Part		AK								
AN A		T	Т		FORE	GN PATENT DOCUMENTS		- <u>- </u>		<u> </u>
AN AN Yes No Yes No AN			DOCL	JMENT NUMBER	DATE	COUNTRY	CL	ASS S	SUB-CLASS	TRANSLATION
AN Yes No Yes No AN Yes No AN Yes No AN		AL								
AN Yes No										
AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR 12 Rosenstein, M., et al., "Extravasation of Intravascular Fluid Mediated by the Systemic Administration of Recombinant Interleukin 2," J. Immunol. 137:1735-1742 (1986). AS 12 Saravolac, E.G., et al., "Effect of Liposome-encapsulation on Immunomodulating and Antiviral Activities of Interferon-y," Antiviral Res. 29:199-207 (March 1996). AT 12 Schmidt, W., et al., "Cancer Vaccines: The Interleukin 2 Dosage Effect," Proc. Natl. Acad. Sci. USA 92:4711-4714 (1995). EXAMINER: Initial-Preference considered, whether or not citation is in conformance with MPEP 609. Draw line through				·.		· · · · · · · · · · · · · · · · · · ·				Yes
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Rosenstein, M., et al., "Extravasation of Intravascular Fluid Mediated by the Systemic Administration of Recombinant Interleukin 2," J. Immunol. 137:1735-1742 (1986). AS 12 Saravolac, E.G., et al., "Effect of Liposome-encapsulation on Immunomodulating and Antiviral Activities of Interferon-y," Antiviral Res. 29:199-207 (March 1996). AT 12 Schmidt, W., et al., "Cancer Vaccines: The Interleukin 2 Dosage Effect," Proc. Natl. Acad. Sci. EXAMINER: Initial Preference considered, whether or not citation is in conformance with MPEP 609. Draw Line through		AN								Yes
AR 12 Rosenstein, M., et al., "Extravasation of Intravascular Fluid Mediated by the Systemic Administration of Recombinant Interleukin 2," J. Immunol. 137:1735-1742 (1986). AS 12 Saravolac, E.G., et al., "Effect of Liposome-encapsulation on Immunomodulating and Antiviral Activities of Interferon-y," Antiviral Res. 29:199-207 (March 1996). AT 12 Schmidt, W., et al., "Cancer Vaccines: The Interleukin 2 Dosage Effect," Proc. Natl. Acad. Sci. EXAMINER: Initial of Terence considered, whether or not citation is in conformance with MPEP 609. Draw line through		AO	+						 	
AR 12 Rosenstein, M., et al., "Extravasation of Intravascular Fluid Mediated by the Systemic Administration of Recombinant Interleukin 2," J. Immunol. 137:1735-1742 (1986). AS 12 Saravolac, E.G., et al., "Effect of Liposome-encapsulation on Immunomodulating and Antiviral Activities of Interferon-y," Antiviral Res. 29:199-207 (March 1996). AT 12 Schmidt, W., et al., "Cancer Vaccines: The Interleukin 2 Dosage Effect," Proc. Natl. Acad. Sci. EXAMINER: Initial Proference considered, whether or not citation is in conformance with MPEP 609. Draw line through		AP								
Administration of Recombinant Interleukin 2," J. Immunol. 137:1735-1742 (1986). AS 12 Saravolac, E.G., et al., "Effect of Liposome-encapsulation on Immunomodulating and Antiviral Activities of Interferon-y," Antiviral Res. 29:199-207 (March 1996). AT 12 Schmidt, W., et al., "Cancer Vaccines: The Interleukin 2 Dosage Effect," Proc. Natl. Acad. Sci. USA 92:4711-4714 (1995). EXAMINER: Initial Preference considered, whether or not citation is in conformance with MPEP 609. Draw line through				OTHER (Including Author	, Title, Date, Pertinen	nt Pages, etc.	.)		
Activities of Interferon-y," Antiviral Res. 29:199-207 (March 1996). AT 12 Schmidt, W., et al., "Cancer Vaccines: The Interleukin 2 Dosage Effect," Proc. Natl. Acad. Sci. USA 92:4711-4714 (1995). EXAMINER: Initial Preference considered, whether or not citation is in conformance with MPEP 609. Draw line through	8	AR	<u>12</u>	Rosenstein, Administrat	M., et al., "Exion of Recombina	travasation of Intravasc nt Interleukin 2," <i>J. In</i>	cular Fluid M mmunol. 137:17	ediated by 735-1742 (*	the Syste	emic
EXAMINER: Initial Preference considered, whether or not citation is in conformance with MPEP 609. Draw line through		AS	<u>12</u>	Saravolac, Activities	E.G., et al., "E of Interferon-y,	ffect of Liposome-encaps " Antiviral Res. 29:199-	sulation on I -207 (March 19	mmunomodul 996).	ating and	Antiviral
EXAMINER: Initial preference considered, whether or not citation is in conformance with MPEP 609. Draw line through		AT	12	Schmidt, W. USA 92:4711	, et al., "Cance -4714 (1995).	r Vaccines: The Interlet	ukin 2 Dosage	Effect,"	Proc. Natl	. Acad. Sci.
EXAMINER: Initial is reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	EXAMINER	ADI	an	y			DATE	CONSIDER	ED 8	19/0)
	EXAMINER: Ini	tially till co	refer	ence consider nce and not c	ed, whether or n onsidered. Incl	ot citation is in confo ude copy of this form w	rmance with M ith next comm	PEP 609. unication	Draw line to Applica	through ant.

EIVEW.

NON 08 SOUL

Page 13 of 16

TECH DE MAPPLICATION NO. ATTY. DOCKET NO. 0652.2050000 09/529,659 FORM PTO-1449 **APPLICANT** Wagner et al INFORMATION DISCLOSURE STATEMENT GROUP 164 102(e) DATE June 22, 2000 U.S. PATENT DOCUMENTS **EXAMINER** CLASS SUB-CLASS FILING DATE DOCUMENT NUMBER DATE NAME INITIAL AA AB AC AD ΑE AF AG ΑН ΑI ΑJ ΑK FOREIGN PATENT DOCUMENTS EXAMINER SUB-CLASS TRANSLATION COUNTRY CLASS DOCUMENT NUMBER DATE INITIAL Yes No AL Yes No AΜ Yes No AN Yes No AO Yes AΡ OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Schmidt, W., et al., "Transloading of Tumor Cells with Foreign Major Histocompatibility Complex Class I Peptide Ligand: A Novel General Strategy for the Generation of Potent Cancer Vaccines," <u>13</u> AR Proc. Natl. Acad Sci. USA 93:9759-9763 (September 1996). Schweighoffer, T., et al., "Adenovirus-enhanced Receptor-mediated Transferrinfection for the <u>13</u> AS Generation of Tumor Vaccines," Cytokines Mol. Ther. 2:185-192 (September 1996). van Slooten, M.L., et al., "Liposomal Encapsulation of Cytokines to Achieve Paracrine Cytokine ΑT <u>13</u> Dleivery in Tumor Vaccine Development," J. Liposome Res. 8:118 (May 1998). DATE CONSIDERED EXAMINER EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

NON 08 SOUCI

·								.ea 186	10 05 16
-					ATTY. DOCKET NO.		APPL 16	CHICEN NO.	11.62
		EODM D	TO-1449		0652.2050000		09/529		NOV 0 7 2000 5
					Wagner et al.			PATE	NOV 0 7 2000
<u>IN</u>	FORMATIO	N DISC	CLOSURE STATE	MENT	102(e) DATE		GROUP	. 1	
					June 22, 2000		-1643-	1642	Q QEMASY OF
				U.S.	PATENT DOCUMENTS	<u> </u>		r -	I
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME	CLA	ss	SUB-CLASS	FILING DATE
INTTAL	AA	1 2000.	TERT HOUSE						
	AB								
	AC								
	AD				<u> </u>				
	AE			7					
	AF								
	AG	ļ							
	AH								
- w-	AI								
	AJ	-							
	AK			EODE 1	GN PATENT DOCUMENTS			<u> </u>	
EXAMINER	ſ-	Ι		FORETO	IN PATENT DOCUMENTS	<u> </u>			
INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLA	ss	SUB-CLASS	TRANSLATION
	AL								Yes No
									Yes No
	AM								Yes
	AN							· ·	No Yes
	AO								No Yes
	AP								No.
			OTHER (Including Author	, Title, Date, Pertinent Pag	ges, etc.			
9	AR	<u>14</u>	Zatloukal, I an Il-2-base 154:3406-34	ed Vaccine. Asses	citation of a Systemic and P esment of Critical Cellular	rotective and Molec	Anti-me ular Pa	elanoma Immu rameters,"	une Response by J. Immunol.
	AS	<u>14</u>			ntic Gene Therapy for Cancer " <i>Gene 135</i> :199-207 (1993).	: The Uti	lity of	Transferrin	nfection in
	AT	<u>14</u>		nd B. Gansbacher, -1264 (1995).	ייThe Impact of Gene Therap	oy on T Ce	ll Func	tion in Cand	cer," Hum. Gene
EXAMINER &	Dari	enl	 ح			DATE	CONSTO	RED 0	
EXAMINER: Init	alif	efere	nce consider	ed, whether or no	ot citation is in conformance	e with MP	EP 609	Draw line	
citation if not	In conf	torman	ce and not co	onsidered. Inclu	de copy of this form with n	ext commu	nicatio	TO APPLICA	ant.

RECEIVED NOV 0.9 2000

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 0652.2050000

APPLICANT

Wagner et al

102(e) DATE

NOV 0 7 2000 GROUP

					June 22, 2000	1643	1642	- KAROEMOK
				י ד	.S. PATENT DOCUMENTS			~C.DO
EXAMINER INITIAL		DOC:	UMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA							
	AB	ļ						
	AC	1						
	AD	-					1	
	AE	-		1				
	AF	+						
	AG	-		-				
	AH	<u> </u>		;			+	
	AJ	+						
	AK	\dagger						
	H			FOR	EIGN PATENT DOCUMENT	s		
XAMINER NITIAL		DOC	UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATIO
	AL							Ye 1
	AM							Ye I
	AN							Ye I
	AO							Ye I
• • •	AP							Y∈ 1
			OTHER (In	cluding Auth	or, Title, Date, Per	tinent Pages, etc.)		
B	AR	<u>15</u>	Dialog f Document (2000).	ile 351, unv No. AP1, De	verified English lang erwent World Patents	guage abstract of DE Index Accession No.	2 44 11 42 1995-363	25 A1, 7006/199548
	AS	15			verified English lang erwent World Patents			
	АТ	<u>15</u>		J.L., "Prot ol. 10:1-43	cein Delivery from Bi	odegradable Microsp	heres," 1	Pharm.
XAMINER	Par	م م	Ó		- 44 - 14 - 44 - 44 - 44 - 44 - 44 - 44	DATE CONS	IDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through praction if not in conformance and not considered. Include copy of this form with next communication to Applicant.



NON 08 SOOK

OIP

Page 16 APPLICATION OF ATTY. DOCKET NO. 0652.2050000 FORM PTO-1449 **APPLICANT** Wagner et al INFORMATION DISCLOSURE STATEMENT 102(e) DATE **GROUP** 1643 June 22, 2000 U.S. PATENT DOCUMENTS **EXAMINER** FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS INITIAL AΑ AB AC AD ΑE ΑF AG ΑН ΑI ΑJ ΑK FOREIGN PATENT DOCUMENTS **EXAMINER** CLASS SUB-CLASS TRANSLATION COUNTRY INITIAL DOCUMENT NUMBER DATE No AL Yes No AM Yes Νo AN Yes No ΑO Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Fujioka, et al., "Long-acting delivery system of interferon: IFN minipellet," J. Controlled Release 33:317-323 (1995). AR <u>16</u> AS <u>16</u> AT <u>16</u> DATE CONSIDERED **EXAMINER** EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.